B. Riley Has Pessimistic View of MDGL FY2025 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – B. Riley reduced their FY2025 earnings per share estimates for shares of Madrigal Pharmaceuticals in a report released on Tuesday, November 4th. B. Riley analyst W. Wood now anticipates that the biopharmaceutical company will earn ($8.24) per share for the year, down from their previous estimate of ($4.91). B. Riley currently has a “Buy” rating and a $560.00 target price on the stock. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share. B. Riley also issued estimates for Madrigal Pharmaceuticals’ Q4 2025 earnings at $1.96 EPS, Q1 2026 earnings at $3.02 EPS, Q2 2026 earnings at $4.40 EPS, Q3 2026 earnings at $4.84 EPS, FY2026 earnings at $17.54 EPS, FY2027 earnings at $29.89 EPS and FY2028 earnings at $56.96 EPS.

A number of other research firms also recently commented on MDGL. Cowen reiterated a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, August 26th. Piper Sandler boosted their price target on Madrigal Pharmaceuticals from $400.00 to $540.00 and gave the company an “overweight” rating in a report on Wednesday, October 15th. Citizens Jmp upped their price target on Madrigal Pharmaceuticals from $485.00 to $527.00 and gave the company a “market outperform” rating in a research report on Wednesday. TD Cowen lifted their price objective on shares of Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the stock a “buy” rating in a report on Tuesday, August 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a report on Wednesday, October 8th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $528.42.

Madrigal Pharmaceuticals Price Performance

MDGL opened at $488.58 on Friday. The company has a market capitalization of $10.85 billion, a P/E ratio of -38.02 and a beta of -1.04. The company has a 50-day moving average of $436.11 and a 200-day moving average of $356.34. The company has a debt-to-equity ratio of 0.17, a quick ratio of 4.78 and a current ratio of 5.11. Madrigal Pharmaceuticals has a 1-year low of $265.00 and a 1-year high of $496.98.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($5.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.01) by ($3.07). Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%. The company had revenue of $287.27 million during the quarter, compared to analyst estimates of $244.33 million.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Assetmark Inc. raised its position in shares of Madrigal Pharmaceuticals by 3.3% during the 3rd quarter. Assetmark Inc. now owns 5,058 shares of the biopharmaceutical company’s stock worth $2,320,000 after buying an additional 160 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Madrigal Pharmaceuticals by 3.4% during the third quarter. Rhumbline Advisers now owns 27,263 shares of the biopharmaceutical company’s stock valued at $12,504,000 after acquiring an additional 900 shares during the period. Baader Bank Aktiengesellschaft bought a new stake in Madrigal Pharmaceuticals during the third quarter worth approximately $885,000. Bryce Point Capital LLC acquired a new stake in Madrigal Pharmaceuticals in the third quarter worth approximately $536,000. Finally, Smartleaf Asset Management LLC boosted its stake in Madrigal Pharmaceuticals by 143.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 124 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 73 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insider Activity

In other Madrigal Pharmaceuticals news, General Counsel Shannon T. Kelley sold 1,304 shares of the business’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $367.81, for a total transaction of $479,624.24. Following the completion of the transaction, the general counsel owned 9,173 shares in the company, valued at approximately $3,373,921.13. The trade was a 12.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kenneth Bate sold 10,000 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $365.20, for a total value of $3,652,000.00. Following the completion of the transaction, the director directly owned 2,627 shares of the company’s stock, valued at approximately $959,380.40. The trade was a 79.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 165,683 shares of company stock worth $61,921,142 and have sold 248,642 shares worth $91,388,103. Insiders own 21.50% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.